ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jun 2024
Last Updated on 04 Jun 2024
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Sofosbuvir 400 mg/velpatasvir 100 mg tablets
in line with its registered indications for treating chronic hepatitis C.

Funding status

Sofosbuvir 400 mg/velpatasvir 100 mg tablet is recommended for inclusion on the Standard Drug List (SDL) from 1 August 2024.

Of note, glecaprevir 100 mg/pibrentasvir 40 mg tablet will be delisted from the MOH List of Subsidised Drugs with effect from 1 February 2025.
Direct-acting antiviral agents for treating chronic hepatitis C (Published 4 Jun 24)